S753
Clinical - Lung
ESTRO 2026
References: 1.
in 30 fractions; Carboplatin/Paclitaxel Q1W for 6 weeks), and if no evidence of PD, cIT (durvalumab). Post-cCRT CT scans were performed within 4 weeks following cCRT completion and subsequently at Q8W intervals. The primary endpoint is ORR (RECIST 1.1) with secondary endpoints of DCR and PFS. This report describes preliminary results as assessed by investigators.
Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. N Engl J Med. 2017;377(20). doi:10.1056/nejmoa17099372. Brade A, Jao K, Yu S, et al. A canadian perspective on the challenges for delivery of curative-intent therapy in stage III unresectable non-small cell lung cancer. Curr Oncol. 2021;28(3). doi:10.3390/curroncol28030151 Keywords: Quality Improvement Radiographic Response in Patients with Stage III Unresectable Non-Small Cell Lung Cancer Treated with an Intratumoral Radioenhancer (JNJ- 90301900) Jeffrey Bradley 1 , Benjamin T. Cooper 2 , Sushma Patel 3 , David DiBardino 4 , Michael Pritchett 5 , Kevin C. Ma 4 , Isaac Laniado 6 , Melina Marmarelis 7 , Matthew Scarlotta 8 , Joshua Sabari 9 , Yi-Wen Ma 10 , Tori Stromp 10 , Yina Kuang 10 , Balaji Laxmanan 10 , Kiran Devisetty 10 , Steven Feigenberg 1 1 Radiation Oncology, University of Pennsylvania, Philadelphia, USA. 2 Radiation Oncology, NYU Langone Health, New York, USA. 3 Radiation Oncology, FirstHealth of the Carolinas, Pinehurst, USA. 4 Interventional Pulmonology, University of Pennsylvania, Philadelphia, USA. 5 Interventional Pulmonology, FirstHealth of the Carolinas, Pinehurst, USA. 6 Interventional Pulmonology, NYU Langone Health, New York, USA. 7 Medical Oncology, University of Pennsylvania, Philadelphia, USA. 8 Medical Oncology, FirstHealth of the Carolinas, Pinehurst, USA. 9 Medical Mini-Oral 116 Oncology, NYU Langone Health, New York, USA. 10 Interventional Oncology, Johnson & Johnson, New Brunswick, USA Purpose/Objective: To qualify and quantify radiographic changes in patients with Stage III unresectable NSCLC treated with an intratumoral/intranodal injection of a novel nanoparticle radioenhancer followed by concurrent chemoradiotherapy (cCRT) followed by consolidation immunotherapy (cIT). Material/Methods: CONVERGE is a two-part Phase 2 study of JNJ-1900, an intratumoral/intranodal injection of radiopaque hafnium oxide nanoparticles (Fig. 1), used as a radioenhancer1 in patients with Stage III unresectable NSCLC. Part 1 enrolled treatment-naïve patients evaluating 2 dose levels of JNJ-1900 to determine safety and feasibility leading to a randomized Part 2. All Part 1 patients received a one-time intratumoral/intranodal administration of JNJ-1900 into at least one target lesion followed by cCRT (60 Gy
Results: There are 7 patients enrolled in Part 1, with 3 in dosing cohort A and 4 in dosing cohort B. In total, 7 lung tumors (median=35mm, 12-74) and 9 lymph nodes (median=13mm, 10-22) were injected. All intratumoral/intranodal injections were performed bronchoscopically. There was 1 Grade 3 TEAE (non- cardiac chest pain) attributed to JNJ-1900 and the injection procedure, which did not delay further treatment. All patients completed cCRT and underwent planned interval CT scans. Upon completion of cCRT, the first CT scans resulted in 5 patients with PR and 2 patients with SD (post-cCRT ORR=71%, DCR=100%) with median response of - 44.6% (0, -76%). For the following disease evaluations during cIT, 1 patient with SD post-cCRT evolved into a CR (-28.6% to -100.0%), 1 maintained initial response (- 47.3% to –45.9%), and 3 became non-evaluable by RECIST due to post-radiation fibrosis or presence of JNJ-1900 radiopacity. To date, best-ORR is 85.7% and DCR is 100% with a median follow up of 4.7 months (2.3, 8.3). Conclusion: Initial results demonstrated feasibility and safety of intratumoral/intranodal injection of JNJ-1900. Post- cCRT, early responses by RECIST criteria were reported in 5/7 patients with a subsequent deepening of response for those evaluable. Despite post-radiation fibrosis and drug radiopacity impacting subsequent assessments, encouraging early favorable responses and absence of PD suggests potential for long-term durability. References: 1.Bonvalot et al. NBTXR3, a first-in-class radioenhancer
Made with FlippingBook - Share PDF online